Goldman Sachs suspended the firm’s rating on Esperion Therapeutics citing insufficient information on which to base an investment view. The move comes after the company disclosed a disagreement with Daiichi Sankyo Europe over its right to receive milestone payments.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ESPR:
- Esperion Tanks after Dispute with Daiichi Sankyo
- Esperion reports disagreement with Daiichi Sankyo over milestone payments
- Esperion says ILEP recommends use of bempedoic acid ahead of PCSK9 inhibitors
- Esperion upgraded to Neutral from Underperform at Credit Suisse
- Esperion Tanks on Nexletol Cardiovascular Data
